U.S. jury decides $250 million damages against Novartis

Daniel Vasella (R), Chairman and Chief Executive Officer (CEO) of Swiss drugmaker Novartis and newly announced CEO Joe Jimenez attend the annual news conference in Basel January 26, 2010. REUTERS/Pascal Lauener

Daniel Vasella (R), Chairman and Chief Executive Officer (CEO) of Swiss drugmaker Novartis and newly announced CEO Joe Jimenez attend the annual news conference in Basel January 26, 2010.

Credit: Reuters/Pascal Lauener

NEW YORK | Wed May 19, 2010 11:45am EDT

NEW YORK (Reuters) - Drugmaker Novartis AG must pay $250 million in punitive damages to more than 5,000 current and former women employees, a jury ruled on Wednesday, two days after finding a U.S. division of the company discriminated against women over pay, promotion and pregnancy.

The jury in U.S. District Court in New York decided that Novartis should pay punitive damages to the entire class of about 5,600 women stemming from a lawsuit filed in 2004.

Presiding Judge Colleen McMahon will determine back pay, lost benefits and adjusted wages for each member of the class.

A Novartis spokeswoman, Pamela McKinlay, said she could not immediately comment on the jury's decision over punitive damages.

David Sanford, a lawyer for the women, said he was delighted.

"This is a vindication of everything that has happened in this courtroom over the last two months," Sanford told reporters after the verdict.

He said the verdict had sent a message to Novartis and other companies that "they cannot continue to get away with the discrimination and systemic problems that have occurred for so long."

In the first part of their ruling on Monday, the jury awarded $3.3 million in compensatory damages to 12 of the women who testified at the 6-week long trial. The award to the 12 women opens the door for the 5,588 other women in the class who can now also apply for compensatory damages.

Sanford had argued in court on Tuesday that the jury should award between $190 million and $285 million in punitive damages, which is about 2 to 3 percent of the company's $9.5 billion 2009 revenue.

Novartis lawyer, Richard Schnadig, told the jury that not all of the plaintiffs agreed with the lawsuit and the company was already pushing ahead with changes.

The case is Velez et al v Novartis Corporation, U.S. District Court for the Southern District of New York, No. 04-09194.

(Reporting by Basil Katz and Grant McCool, editing by Dave Zimmerman)

Related Quotes and News

Company
Price
Related News
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (5)
DonCiccio wrote:
50K each not bad.

May 19, 2010 11:29am EDT  --  Report as abuse
CadronBoy wrote:
This is nothing. Novaritis also produces bis-phosphonates such as Aredia and Zometa which causes osteonecorsis of the jaw (ONJ). These medications like Fosamax, Boniva and Actonel have resulted in many women losing their entire jaw — a most serious deformity. And unfortunately once ONJ sets in the jaw literally often rots away right down to the base of the skull. Novartis has now issued a statement regarding this complication but has yet to offer any restitution to those women who are now dental cripples unable to eat or speak.

May 19, 2010 11:50am EDT  --  Report as abuse
tattoodave wrote:
I hate to say it because it sounds really religious but WWJD? If He were allowed to decide whether or not women should be paid the same as men, it might have looked like this. Too bad the ones awarded damages will have to wait so long to recieve just compensation@!

May 19, 2010 12:43pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.